# A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

> **NCT02412371** · PHASE1,PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 48 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage III

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Placebo for Veliparib
- **DRUG:** Carboplatin
- **DRUG:** Veliparib
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT02412371
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-30
- **Primary completion:** 2019-08-05
- **Final completion:** 2019-08-05
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable Stage III NSCLC
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02412371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02412371, "A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02412371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*